The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okada, N.
Right arrow Articles by Okada, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okada, N.
Right arrow Articles by Okada, H.

The Journal of Immunology, Vol 143, Issue 7 2262-2266, Copyright © 1989 by American Association of Immunologists

ARTICLES

Monoclonal antibodies capable of causing hemolysis of neuraminidase- treated human erythrocytes by homologous complement

N Okada, R Harada, T Fujita and H Okada
Department of Microbiology, Fukuoka University School of Medicine, Japan.

As human E (HuE) treated with neuraminidase (Neu) are resistant to hemolysis by human serum but are readily lysed by heterologous serum via the alternative C pathway, we attempted to produce mAb which might modify Neu-treated HuE (Neu-HuE) so as to render them sensitive to homologous C. A hybridoma, clone -1F5, was obtained by screening for antibody which caused hemolysis of Neu-HuE by human serum via the alternative C pathway. We have shown that this antibody (1F5) of IgG1 isotype blocks the action of a 20-kDa membrane inhibitor capable of interfering with the terminal step in the homologous C cascade. The antigenic molecule can be termed HRF20, which stands for homologous restriction factor (HRF) with m.w. 20,000, because its function is essentially the same as that of HRF (68,000) reported by others.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. Ohta, N. Kondor, N. Dohi, S. Tomlinson, M. Imai, V. M. Holers, H. Okada, and N. Okada
Mouse Complement Receptor-Related Gene y/p65-Neutralized Tumor Vaccine Induces Antitumor Activity In Vivo
J. Immunol., July 1, 2004; 173(1): 205 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Chen, J. R. Eshleman, R. A. Brodsky, and M. E. Medof
Glycophosphatidylinositol-anchored Protein Deficiency as a Marker of Mutator Phenotypes in Cancer
Cancer Res., January 1, 2001; 61(2): 654 - 658.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Yu, S. Nagarajan, J. J. Knez, S. Udenfriend, R. Chen, and M. E. Medof
The affected gene underlying the class K glycosylphosphatidylinositol (GPI) surface protein defect codes for the GPI transamidase
PNAS, November 11, 1997; 94(23): 12580 - 12585.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Shichishima, Y. Saitoh, T. Terasawa, K. Ogawa, and Y. Maruyama
Relationship Between the Phenotypes of Circulating Erythrocytes and Cultured Erythroblasts in Paroxysmal Nocturnal Hemoglobinuria
Blood, July 1, 1997; 90(1): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
I. Farkas, L. Baranyi, Y. Ishikawa, N. Okada, C. Bohata, D. Budai, A. Fukuda, M. Imai, and H. Okada
CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9
J. Physiol., March 1, 2002; 539(2): 537 - 545.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1989 by The American Association of Immunologists, Inc. All rights reserved.